Alimera racks up another Iluvien approval with German nod
This article was originally published in Scrip
Alimera Sciences has gained its fifth national approval in Europe approval for Iluvien (fluocinolone acetonide) as the Federal Ministry of Health of Germany today granted marketing authorisation for the treatment of vision impairment associated with chronic diabetic macular oedema.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.